Beck Capital Management LLC trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 36.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 4,215 shares of the medical research company’s stock after selling 2,464 shares during the period. Beck Capital Management LLC’s holdings in Charles River Laboratories International were worth $455,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. YorkBridge Wealth Partners LLC lifted its holdings in shares of Charles River Laboratories International by 445.5% during the third quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock valued at $118,000 after purchasing an additional 891 shares during the last quarter. Advisor Group Inc. lifted its holdings in shares of Charles River Laboratories International by 159.4% during the third quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock valued at $165,000 after purchasing an additional 945 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Charles River Laboratories International by 12.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 202 shares during the last quarter. Riverhead Capital Management LLC lifted its holdings in shares of Charles River Laboratories International by 14.7% during the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock valued at $195,000 after purchasing an additional 247 shares during the last quarter. Finally, Advisor Partners LLC purchased a new position in shares of Charles River Laboratories International during the second quarter valued at approximately $208,000. Hedge funds and other institutional investors own 96.27% of the company’s stock.

Several research firms have recently issued reports on CRL. Robert W. Baird set a $117.00 target price on shares of Charles River Laboratories International and gave the company a “buy” rating in a report on Monday, November 13th. Zacks Investment Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $110.00 target price for the company in a report on Thursday, August 10th. Bank of America lowered their target price on shares of Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating for the company in a report on Friday, November 10th. Jefferies Group lifted their target price on shares of Charles River Laboratories International from $120.00 to $130.00 and gave the company a “buy” rating in a report on Monday, October 9th. Finally, Royal Bank Of Canada began coverage on shares of Charles River Laboratories International in a report on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 target price for the company. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $106.63.

Charles River Laboratories International, Inc. (NYSE:CRL) opened at $102.48 on Thursday. Charles River Laboratories International, Inc. has a 1-year low of $72.06 and a 1-year high of $119.05. The firm has a market cap of $4,822.35, a P/E ratio of 20.00, a P/E/G ratio of 1.62 and a beta of 0.89. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. The company had revenue of $464.23 million during the quarter, compared to analyst estimates of $458.93 million. During the same period in the previous year, the business earned $1.18 EPS. The firm’s revenue for the quarter was up 9.0% on a year-over-year basis. analysts anticipate that Charles River Laboratories International, Inc. will post 5.13 earnings per share for the current year.

In other Charles River Laboratories International news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the business’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $0.27, for a total transaction of $270,000.00. Also, insider Davide Molho sold 6,165 shares of the business’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $110.00, for a total transaction of $678,150.00. The disclosure for this sale can be found here. Over the last 90 days, insiders purchased 10,500 shares of company stock valued at $2,885. 2.20% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Beck Capital Management LLC Cuts Holdings in Charles River Laboratories International, Inc. (CRL)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/07/beck-capital-management-llc-cuts-holdings-in-charles-river-laboratories-international-inc-crl.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.